Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

The significance of the gut microbiome in post-COVID-19 gastrointestinal symptoms

Temi Lampejo
Download PDF
DOI: https://doi.org/10.7861/clinmed.Let.22.2.5
Clin Med March 2022
Temi Lampejo
Consultant in infectious diseases and virology, Kingʼns College Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Editor – I read with interest the article by Cooney and colleagues in which 43.8% of the patients studied reported new-onset gastrointestinal (GI) symptoms in the 6 months after their acute COVID-19 illness and the authors suggest the possible existence of a post-COVID-19 irritable bowel syndrome (IBS).1 The authors discuss the presence of the angiotensin converting enzyme 2 (ACE-2) receptor throughout the GI tract, which serves as the SARS-CoV-2 receptor, as an important potential factor. However, the potential relevance of gut microbiome disturbance in patients with COVID-19 was not discussed.

Significant alterations in the gut microbiome have been demonstrated in patients with COVID-19 compared with non-COVID-19 controls, characterised by an abundance of opportunistic pathogens and a reduction in certain gut commensals known to have anti-inflammatory properties including Faecalibacterium prausnitzii and Bifidobacterium.2 A meta-analysis also found significant reductions in both of these gut commensals in IBS patients when compared with healthy controls.2 Additionally, multiple studies have reported reduced levels of F prausnitzii in the gut of patients with inflammatory bowel disease.4

The degree of gut dysbiosis in COVID-19 has been demonstrated to correlate with the severity of COVID-19 illness and dysbiosis has been shown to persist in a subset of patients even after clearance of SARS-CoV-2 RNA.5,6 However, antibiotics are also likely to play a role, at least in part, supported by the fact that alterations in the gut microbiome have also been identified in patients treated for (non-COVID-19) community-acquired pneumonia.6 Empirical broad-spectrum antibiotic usage in patients hospitalised with COVID-19 is high (>60%), particularly in individuals with severe disease and, in the study by Cooney et al, 97% were admitted for inpatient care with 36% requiring intensive care unit care.1,7 Broad-spectrum antibiotics have been shown to negatively impact the gut microbiota resulting in reduced microbial diversity and potentially beneficial bacteria.8 Furthermore, an association between the use of certain antibiotic classes (macrolides and tetracyclines) within the prior 12 months and the development of IBS has been demonstrated.9 Gut microbiome dysbiosis may therefore play a key role in the development of post-COVID-19 GI symptoms and this area needs further study.

  • © Royal College of Physicians 2022. All rights reserved.

References

  1. ↵
    1. Cooney J
    , Appiahene P, Findlay R, et al. COVID-19 infection causing residual gastrointestinal symptoms – a single UK centre case series. Clin Med 2022;22:181–3.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Liu Q
    , Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 2022;71:544–52.
    OpenUrlAbstract/FREE Full Text
    1. Liu HN
    , Wu H, Chen YZ, et al. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Digestive and Liver Disease 2017;49:331–7.
    OpenUrlPubMed
  3. ↵
    1. Wright EK
    , Kamm MA, Teo SM, et al. Recent advances in characterizing the gastrointestinal microbiome in Crohnʼns disease: a systematic review. Inflamm Bowel Dis 2015;21:1219–28.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kariyawasam JC
    , Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg 2021;115:1362–88.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Zuo T
    , Zhan H, Zhang F, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. Gastroenterology 2020;159:1302–10.e5.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Rawson TM
    , Moore LSP, Castro-Sanchez E, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother 2020;75:1681–4.
    OpenUrlPubMed
  7. ↵
    1. Menees S
    , Chey W. The gut microbiome and irritable bowel syndrome. F1000Res 2018;7:F1000 Faculty Rev-1029.
    OpenUrl
  8. ↵
    1. Villarreal AA
    , Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012;111:17–20.
    OpenUrlPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The significance of the gut microbiome in post-COVID-19 gastrointestinal symptoms
Temi Lampejo
Clinical Medicine Mar 2022, 22 (2) 189-190; DOI: 10.7861/clinmed.Let.22.2.5

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The significance of the gut microbiome in post-COVID-19 gastrointestinal symptoms
Temi Lampejo
Clinical Medicine Mar 2022, 22 (2) 189-190; DOI: 10.7861/clinmed.Let.22.2.5
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The association of pleural effusion and pulmonary embolism
  • What is the impact of COVID-19 on complaints against doctors?
Show more Letters to the editor

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians